Karyopharm Therapeutics (NASDAQ: KPTI) EVP shares sold for taxes

Q: What insider transaction did Karyopharm (KPTI) report for Stuart Poulton?

Karyopharm reported that EVP and Chief Development Officer Stuart Poulton had 189 common shares sold on July 28, 2026 at $7.10 per share. The sale was broker-assisted and used to cover withholding taxes from vested restricted stock units.

Q: How many Karyopharm (KPTI) shares does Stuart Poulton hold after this Form 4?

After the reported transaction, Stuart Poulton holds 94,632 Karyopharm common shares directly. The filing indicates this position following the broker-assisted sale of 189 shares to satisfy tax withholding obligations related to restricted stock unit vesting.

Q: What was the sale price in the latest Karyopharm (KPTI) insider trade?

The reported transaction for Karyopharm executive Stuart Poulton involved a sale of 189 common shares at $7.10 per share. The sale was executed by a broker to fund withholding tax liabilities from the vesting of restricted stock units.

Q: Was the Karyopharm (KPTI) insider sale by Stuart Poulton discretionary?

The sale is described as non-discretionary . It was executed under a durable automatic sale instruction plan adopted on May 18, 2022 and was specifically intended to cover withholding tax liability from vested restricted stock units, not as a discretionary portfolio trade.

Q: Why were Karyopharm (KPTI) shares sold in Stuart Poulton’s Form 4 filing?

The 189 shares were sold to satisfy withholding tax liability incurred when restricted stock units vested. According to the filing, this was a broker-assisted, automatic sale under a pre-established instruction plan, rather than a discretionary open-market decision by the executive.

Q: Is the Karyopharm (KPTI) insider sale linked to a trading plan?

Yes. The filing states the transaction occurred under a durable automatic sale instruction plan adopted by Stuart Poulton on May 18, 2022 . The plan directed broker-assisted sales specifically to cover tax withholding from restricted stock unit vesting.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Stuart Poulton, EVP and Chief Development Officer, reported the sale of 189 shares of common stock on July 28, 2026 at $7.10 per share.

The broker-assisted sale was made under a durable automatic sale instruction plan adopted on May 18, 2022 to satisfy withholding tax liability from vested restricted stock units and is described as non-discretionary; Poulton now holds 94,632 shares directly.

Insider Trade Summary

Net Seller: 189 shares

Net Sell 1 txn

Insider Poulton Stuart

Role EVP, Chief Development Officer

Sold 189 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	189	$7.10	$1K

Holdings After Transaction: Common Stock — 94,632 shares (Direct)

Footnotes (1)

F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 189 shares Sale price: $7.10 per share Shares held after sale: 94,632 shares

3 metrics

Shares sold 189 shares Common Stock sale on July 28, 2026

Sale price $7.10 per share Per-share price for 189-share sale on July 28, 2026

Shares held after sale 94,632 shares Direct ownership following July 28, 2026 transaction

Key Terms

durable automatic sale instruction plan, restricted stock units, withholding tax liability, broker-assisted sale

4 terms

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan"

restricted stock units financial

"withholding tax liability incurred upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

withholding tax liability financial

"shares to satisfy the payment of withholding tax liability incurred"

broker-assisted sale financial

"represents a broker-assisted sale of shares to satisfy the payment"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:42 PM Accepted by SEC EDGAR 07/30/2026 - 04:42 PM

FAQ

What insider transaction did Karyopharm (KPTI) report for Stuart Poulton?

Karyopharm reported that EVP and Chief Development Officer Stuart Poulton had 189 common shares sold on July 28, 2026 at $7.10 per share. The sale was broker-assisted and used to cover withholding taxes from vested restricted stock units.

How many Karyopharm (KPTI) shares does Stuart Poulton hold after this Form 4?

After the reported transaction, Stuart Poulton holds 94,632 Karyopharm common shares directly. The filing indicates this position following the broker-assisted sale of 189 shares to satisfy tax withholding obligations related to restricted stock unit vesting.

What was the sale price in the latest Karyopharm (KPTI) insider trade?

The reported transaction for Karyopharm executive Stuart Poulton involved a sale of 189 common shares at $7.10 per share. The sale was executed by a broker to fund withholding tax liabilities from the vesting of restricted stock units.

Was the Karyopharm (KPTI) insider sale by Stuart Poulton discretionary?

The sale is described as non-discretionary. It was executed under a durable automatic sale instruction plan adopted on May 18, 2022 and was specifically intended to cover withholding tax liability from vested restricted stock units, not as a discretionary portfolio trade.

Why were Karyopharm (KPTI) shares sold in Stuart Poulton’s Form 4 filing?

The 189 shares were sold to satisfy withholding tax liability incurred when restricted stock units vested. According to the filing, this was a broker-assisted, automatic sale under a pre-established instruction plan, rather than a discretionary open-market decision by the executive.

Is the Karyopharm (KPTI) insider sale linked to a trading plan?

Yes. The filing states the transaction occurred under a durable automatic sale instruction plan adopted by Stuart Poulton on May 18, 2022. The plan directed broker-assisted sales specifically to cover tax withholding from restricted stock unit vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poulton Stuart

(Last)

(First)

(Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON

MASSACHUSETTS

02459

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/28/2026		S⁽¹⁾		189	D	$7.1	94,632	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR